The muon Smasher's guide
H Al Ali, N Arkani-Hamed, I Banta… - Reports on Progress …, 2022 - iopscience.iop.org
We lay out a comprehensive physics case for a future high-energy muon collider, exploring
a range of collision energies (from 1 to 100 TeV) and luminosities. We highlight the …
a range of collision energies (from 1 to 100 TeV) and luminosities. We highlight the …
[HTML][HTML] JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
…, JJ Kiladjian, HK Al-Ali, H Gisslinger… - … England Journal of …, 2012 - Mass Medical Soc
Background Treatment options for myelofibrosis are limited. We evaluated the efficacy and
safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared …
safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared …
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts
…, T Bernal del Castillo, HK Al-Ali… - Blood, The Journal …, 2015 - ashpublications.org
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and
safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly …
safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly …
[HTML][HTML] High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease
PJ Thornalley, R Babaei-Jadidi, H Al Ali, N Rabbani… - Diabetologia, 2007 - Springer
Aims/hypothesis To assess thiamine status by analysis of plasma, erythrocytes and urine in
type 1 and type 2 diabetic patients and links to markers of vascular dysfunction. Methods …
type 1 and type 2 diabetic patients and links to markers of vascular dysfunction. Methods …
[HTML][HTML] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
…, AM Vannucchi, JJ Kiladjian, HK Al-Ali, H Gisslinger… - Leukemia, 2016 - nature.com
Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral …
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral …
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
…, AM Vannucchi, JJ Kiladjian, HK Al-Ali… - Blood, The Journal …, 2013 - ashpublications.org
Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions
in splenomegaly and marked improvement in disease-related symptoms and quality of …
in splenomegaly and marked improvement in disease-related symptoms and quality of …
Phase III MANIFEST-2: pelabresib+ ruxolitinib vs placebo+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
…, T Devos, E Jourdan, MJ Wondergem, HK Al-Ali… - Future …, 2022 - Future Medicine
… HK Al-Ali has received consulting fees and honoraria from Novartis, Bristol Myers Squibb
and Abbvie, and research funding from Novartis, Bristol Myers Squibb and Incyte. A Alvarez-…
and Abbvie, and research funding from Novartis, Bristol Myers Squibb and Incyte. A Alvarez-…
In vitro models of axon regeneration
… B′, D–D′, F–F′, H–H′) of a neurite growth promoting kinase inhibitor, RO1A03. A–H
show anti-β3 tubulin immunostaining used to visualize the neuronal cytoskeleton (green). A′–…
show anti-β3 tubulin immunostaining used to visualize the neuronal cytoskeleton (green). A′–…
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated …
…, B Rio, A Gratwohl, T Lange, H Al-Ali… - Journal of Clinical …, 2006 - ascopubs.org
Purpose The use of low-dose, irradiation-based preparative regimens have allowed the
extension of allografting to older and medically infirm patients. The study reported here …
extension of allografting to older and medically infirm patients. The study reported here …
Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in …
T Bumm, C Müller, HK Al-Ali, K Krohn… - Blood, The Journal …, 2003 - ashpublications.org
Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion
protein with deregulated tyrosine kinase activity that is required for maintaining the malignant …
protein with deregulated tyrosine kinase activity that is required for maintaining the malignant …